IL163719A0 - Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase - Google Patents

Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase

Info

Publication number
IL163719A0
IL163719A0 IL16371903A IL16371903A IL163719A0 IL 163719 A0 IL163719 A0 IL 163719A0 IL 16371903 A IL16371903 A IL 16371903A IL 16371903 A IL16371903 A IL 16371903A IL 163719 A0 IL163719 A0 IL 163719A0
Authority
IL
Israel
Prior art keywords
oxdiazol
alkoxy
ones
substituted phenyl
inhibitory effect
Prior art date
Application number
IL16371903A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL163719A0 publication Critical patent/IL163719A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16371903A 2002-02-28 2003-02-17 Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase IL163719A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (de) 2002-02-28 2002-02-28 Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
PCT/EP2003/001560 WO2003072098A1 (de) 2002-02-28 2003-02-17 Verwendung substituierter 3-phenyl-5-alkoxy-1,3,4-oxdiazol-2-one zur herstellung von arzneimitteln mit hemmender wirkung an der pankreatischen lipase

Publications (1)

Publication Number Publication Date
IL163719A0 true IL163719A0 (en) 2005-12-18

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16371903A IL163719A0 (en) 2002-02-28 2003-02-17 Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase

Country Status (20)

Country Link
EP (1) EP1482929A1 (xx)
JP (1) JP2005519079A (xx)
KR (1) KR20040101250A (xx)
CN (1) CN1638766A (xx)
AR (1) AR038702A1 (xx)
AU (1) AU2003210292A1 (xx)
BR (1) BR0308045A (xx)
CA (1) CA2477005A1 (xx)
CO (1) CO5611144A2 (xx)
DE (1) DE10208986A1 (xx)
HR (1) HRP20040783A2 (xx)
HU (1) HUP0500093A2 (xx)
IL (1) IL163719A0 (xx)
MA (1) MA27173A1 (xx)
MX (1) MXPA04007480A (xx)
NO (1) NO20044091L (xx)
PL (1) PL371310A1 (xx)
RU (1) RU2004128932A (xx)
TW (1) TW200400026A (xx)
WO (1) WO2003072098A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110595B2 (en) 2004-06-17 2012-02-07 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
EP2246338B1 (en) * 2007-12-25 2013-11-20 Kissei Pharmaceutical Co., Ltd. Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
WO2010074587A2 (en) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
AU2018326396B2 (en) * 2017-09-01 2023-10-26 Falasca, Marco PROF Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleolyl-LPI) and uses thereof
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
NZ521207A (en) * 2000-03-07 2005-04-29 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase

Also Published As

Publication number Publication date
NO20044091L (no) 2004-09-27
WO2003072098A1 (de) 2003-09-04
BR0308045A (pt) 2004-12-21
CA2477005A1 (en) 2003-09-04
KR20040101250A (ko) 2004-12-02
AU2003210292A1 (en) 2003-09-09
MXPA04007480A (es) 2004-11-10
HRP20040783A2 (en) 2005-04-30
HUP0500093A2 (hu) 2005-04-28
DE10208986A1 (de) 2003-09-11
MA27173A1 (fr) 2005-01-03
JP2005519079A (ja) 2005-06-30
PL371310A1 (en) 2005-06-13
EP1482929A1 (de) 2004-12-08
CN1638766A (zh) 2005-07-13
AR038702A1 (es) 2005-01-26
TW200400026A (en) 2004-01-01
RU2004128932A (ru) 2005-04-10
CO5611144A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
HK1249850A1 (zh) 治療多發性硬化症的方法
ZA200500086B (en) Novel carboxamide compounds having an MCH-antagonistic effect, medicaments containing said compounds, and method for the production thereof
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
ZA200302553B (en) Arrangement of radial bogie.
AU2003282094A1 (en) Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
AU2003257465A1 (en) Substituted diaryl heterocycles, method for the production and use thereof as medicaments
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
IL163719A0 (en) Use of substituted phenyl-5-alkoxy-1,3,4-oxdiazol-2-ones for producing medicaments with an inhibitory effect on pancreatic lipase
WO2003079962A3 (de) Zusammenhängende einheit aus vereinzelbaren transdermalen therapeutischen systemen
AU2003233820A1 (en) Method for the treatment of starch
AU2002353510A1 (en) Nebuliser
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
AU2003293477A1 (en) Method for the production of polycarbonates
AU2003210287A1 (en) Coolant distributor
AU2003258622A1 (en) Method for the production of $g(b)-carotinoids
AU2003209534A1 (en) The method of treating tuberculosis
AU2003267541A1 (en) Method for the production of substituted trifluoroethylenes
AU2003218718A1 (en) Utilization of ubiquinones for influencing the effect of histamine
NO20041295L (no) Tieno(1,3)oksazin-4-oner med lipaseinhiberende aktivitet
AU2003245879A1 (en) Method for the production of substituted trifluoroetylenes
AU2003233239A1 (en) Method for the production of polymethylenepolysulfides
AU2003200836A1 (en) Method for the preparation of matairesinol